PTLA Portola Pharmaceuticals Inc.

27.31
-0.65  -2%
Previous Close 27.96
Open 27.79
Price To Book 2731
Market Cap 1,865,921,148
Shares 68,323,733
Volume 656,977
Short Ratio
Av. Daily Volume 1,042,070
Stock charts supplied by TradingView

NewsSee all news

  1. Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for

  2. Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry

  3. Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 22, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2 updated data due at ASH December 2018 noted ORR 34%; 27% CR and in the PTCL cohort ORR 26%; 7% CR.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
Andexxa
Factor Xa inhibitor reversal agent

Latest News

  1. Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for

  2. Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry

  3. Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 22, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual